Last updated on February 2018
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
Brief description of study
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
Detailed Study Description
To determine:
- Duration of response
- Progression free survival
- Proportion of responders 2 years after discontinuation of inecalcitol
- Duration of response after discontinuation of inecalcitol and imatinib
- Bone remodelling effect
- Safety of inecalcitol in combination with imatinib
- Quality of Life
Clinical Study Identifier: NCT02949570
Start Over
Connect »